['asthma']
['bd mdi 320 µg', 'bd mdi 160 µg', 'bd mdi 80 µg', 'bd mdi 40 µg', 'placebo mdi']

        Inclusion Criteria:

          -  ≥ 18 - 65 years of age

          -  Diagnosis of mild to moderate persistent asthma, diagnosed at least 6 months prior to
             screening

          -  Currently receiving treatment with a low to medium dose of an inhaled corticosteroid
             (ICS) OR a combination of controller medications for at least 4 weeks preceding
             screening

          -  Pre-albuterol FEV1 of > 60% and < 85% of predicted normal value

          -  Reversibility: Increase in FEV1 of ≥ 12% and ≥ 200 mL over the pre-albuterol FEV1
             within 30 - 60 minutes after the inhalation of 4 puffs of Ventolin hydrofluoroalkane
             (HFA)

          -  Asthma Symptom Criteria: Have required albuterol use on at least two of the last seven
             days and have an Asthma Control Questionnaire (ACQ) total score ≥ 1.5 prior to
             Randomization

        Exclusion Criteria:

          -  Life-Threatening Asthma: A subject must not have life-threatening asthma defined as a
             history of significant asthma episode(s) requiring intubation associated with
             hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal
             episode(s) within the 12 months prior to screening

          -  Worsening of Asthma: A subject must not have experienced a worsening of asthma which
             involved an emergency department visit, hospitalization or use of oral/parenteral
             corticosteroids within 6 weeks of screening

          -  Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only
             intermittent, seasonal or exercise-induced asthma are excluded from participation in
             this study

          -  Concurrent Respiratory Disease

          -  Pregnant women or nursing mothers

          -  A current diagnosis of Chronic Obstructive Pulmonary Disease (COPD

          -  Current smokers or subjects with a > 10 pack year history of cigarettes, cigars, or
             pipe smoking

          -  Respiratory tract infection within 6 weeks prior to Visit 1

          -  Subjects with documented myocardial infarction within a year from screening visit

          -  Clinically significant abnormal ECG

          -  Abnormal liver function tests defined as aspartate aminotransferase (AST), alanine
             aminotransferace (ALT), alkaline phosphatase or total bilirubin ≥ 1.5 times upper
             limit of normal on repeat testing

          -  Subjects who have cancer that has not been in complete remission for at least 5 years

          -  Drug Allergy: Subjects who have a history of hypersensitivity to any component of the
             metered-dose inhaler (MDI)
      